Login to Your Account

Washington Roundup

FDA Pulls Breast Cancer Indication for Avastin

By Mari Serebrov
Washington Editor

Monday, November 21, 2011
WASHINGTON – Citing a lack of proof that the benefits outweigh the risks, FDA Commissioner Margaret Hamburg revoked the agency's approval of the breast cancer indication for Genentech Inc.'s Avastin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription